Ouabain Protects Mice Against Lipopolysaccharide-Induced Acute Lung Injury

Changli Wang,Yan Meng,Yuanyuan Wang,Zhengyu Jiang,Mengda Xu,Lulong Bo,Xiaoming Deng

DOI: https://doi.org/10.12659/msm.908627

2018-01-01

Medical Science Monitor

Abstract:Background: Ouabain, an inhibitor of Na+/K+-ATPase, is a type of endogenous hormone synthesized in the adrenal cortex and hypothalamus. Previous studies found that ouabain potently inhibited inflammatory reactions and regulated immunological processes. Our present study aimed to investigate the therapeutic role of ouabain on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. Material/Methods: Ouabain (0.1 mg/kg) or vehicles were intraperitoneally injected into male C57BL/61 mice once a day for 3 consecutive days. One hour after the last injection of ouabain, LPS (5 mg/kg) was administrated through intranasal instillation to induce ALI. 6 hours and 24 hours later, bronchoalveolar lavage fluid (BALF) and lung tissues were harvested to detect the protective effects of ouabain, including protein concentration, inflammation cell counts, lung wet-to-dry ratio, and lung damage. Results: The results showed that ouabain attenuated LPS-induced ALI in mice, which was indicated by alleviated path- ological changes, downregulated TNF-alpha, IL-1 beta, and IL-6 production, inhibited neutrophils infiltration and macrophages, and ameliorated pulmonary edema and permeability. Further results found the activation of nuclear factor-kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) signaling pathways were suppressed by ouabain in LPS-induced ALI. Conclusions: These results suggest that ouabain negatively modulates the severity of LPS-induced ALI.